Pfizer-Biontech’s COVID-19 Vaccine was authorized for use in children 5 – 11

The first in the U.S. to receive emergency use authorization (EUA) in this younger age group, the FDA announced Friday.

The agency amended the existing EUA to include children ages 5 to 11 after the vaccine produced an immune response that was comparable to the response seen in people ages 16 to 25, and showed 91% efficacy in a small descriptive analysis.

On Tuesday, November 2, the CDC’s Advisory Committee on Immunization Practices will meet to discuss further clinical recommendations.